Trend/Momentum: MACD histogram at -0.451 is below zero and negatively expanding, signaling strengthening downside momentum.
RSI: RSI(6) at 24.54 indicates oversold conditions, but oversold can persist while the downtrend continues.
Moving averages: converging MAs suggest consolidation, but not yet a confirmed reversal.
Key levels: Current price 8.25 is below S1 (8.363), a bearish breakdown; next support is S2 (7.631). Upside reclaim levels: pivot 9.55, then R1 10.736.
Pattern-based forward bias: similar-candlestick study implies ~-5.81% over the next week despite a modest positive next-month skew (+3.92%), reinforcing near-term caution.
Positive Catalysts
and reiterated Buy on 2026-01-21, citing favorable safety profile for LPCN
Fundamentals show reduced losses vs. last year (improving profitability trend, even though still negative).
Neutral/Negative Catalysts
Revenue is effectively flat YoY, so the near-term narrative relies more on pipeline/clinical sentiment than operating growth.
Net income: -3,186,832, improved ~43.63% YoY (loss narrowing).
EPS: -0.59, improved ~43.90% YoY (still negative, but trending better).
Gross margin: 100 (unchanged), likely reflecting the company’s revenue mix rather than broad operating leverage.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: H.C. Wainwright maintained a Buy rating across updates, but shifted price target down to $7 after Q3 (2025-11-13) and then sharply raised it to $15 (2026-01-21) on improved safety/read-through commentary.
Wall Street pro view (pros): bullish single-analyst conviction and upgraded target suggests perceived upside tied to product/pipeline developments.
Wall Street con view (cons): limited analyst coverage and the stock’s current bearish technical setup conflict with the optimistic target; execution and catalyst timing risk remain.
Influential/political flows: No recent congress trading data available; hedge funds and insiders both reported as neutral (no notable accumulation signal).
Wall Street analysts forecast LPCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LPCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.720
Low
6.75
Averages
6.88
High
7
Current: 7.720
Low
6.75
Averages
6.88
High
7
H.C. Wainwright
NULL -> Buy
upgrade
$7 -> $15
AI Analysis
2026-01-21
Reason
H.C. Wainwright
Price Target
$7 -> $15
AI Analysis
2026-01-21
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Lipocine to $15 from $7 and keeps a Buy rating on the shares. The firm says LPCN 1154 showed a favorable safety profile.
H.C. Wainwright
H.C. Wainwright
Buy -> Buy
downgrade
$8 -> $7
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$8 -> $7
2025-11-13
downgrade
Buy -> Buy
Reason
H.C. Wainwright lowered the firm's price target on Lipocine to $7 from $8 and keeps a Buy rating on the shares following the Q3 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LPCN
